J.P. Morgan Reaffirms Their Buy Rating on Bayer (0P6S)
J.P. Morgan analyst Richard Vosser maintained a Buy rating on Bayer today and set a price target of €50.00.
Claim 50% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
According to TipRanks, Vosser is a 4-star analyst with an average return of 3.0% and a 51.48% success rate. Vosser covers the Healthcare sector, focusing on stocks such as Roche Holding AG, Bayer, and Merck KGaA.
In addition to J.P. Morgan, Bayer also received a Buy from Barclays’s James Gordon CFA in a report issued on January 20. However, yesterday, TipRanks – Anthropic reiterated a Hold rating on Bayer (LSE: 0P6S).
Based on Bayer’s latest earnings release for the quarter ending September 30, the company reported a quarterly revenue of €9.66 billion and a GAAP net loss of €963 million. In comparison, last year the company earned a revenue of €9.97 billion and had a GAAP net loss of €4.18 billion
Read More on GB:0P6S:
Disclaimer & DisclosureReport an Issue
- Bayer, Vanderbilt University Medical Center enter five-year collaboration
- Bayer ‘welcomes’ Supreme Court review of Durnell litigation
- U.S. Supreme Court to hear Bayer’s appeal of Roundup lawsuits, Bloomberg says
- Bayer to acquire AT-01 and AT-05 from Attralus, terms undisclosed
- Bayer, Souffle Therapeutics report global licensing agreement for siRNA therapy
